Surge in incidence of cancers worldwide, growth in geriatric population, rise in cancer R&D are anticipated to help the market gain traction during the forecast
PORTLAND, OR, UNITED STATES, November 16, 2021 /EINPresswire.com/ — Cancer immunotherapy, also known as biologic therapy, helps in cancer treatment by boosting the immunity of the body to fight against cancer. In this type of therapy antibodies and live viruses are introduced in the body that slows the growth of cancer cells. In addition, it also helps the immune system destroy the cancer cells. The major factors that drive the growth of this market include increase in incidence of cancers, growth in geriatric population, and rise in cancer R&D. However, shortage of skilled labor and lack of awareness about cancer immunotherapy is projected to restrain the market growth during the forecast period.
The global cancer immunotherapy market was valued at $85,603.50 million in 2020, and is projected to reach $309,667.65 million by 2030, registering a CAGR of 14.1% from 2021 to 2030. The monoclonal antibodies segment held two-third share of the total market in 2020. The report offers a detailed analysis of the key segments, top investment pockets, changing dynamics, market size & estimations, and competitive scenario.
Download Free Report Sample @ https://www.alliedmarketresearch.com/request-sample/2244
The cancer immunotherapy market in this report is studied on the basis of technology, application, end-user, and region. Based on technology, the market is divided into monoclonal antibodies, cytokines & immunomodulators, and other technologies. Monoclonal antibodies held the largest share in 2015 owing to high usage of monoclonal antibodies for cancer immunotherapy as they exhibit different immunomodulatory properties and hence they can directly activate or inhibit the molecules of immune system. In addition, monoclonal antibodies also induce the antitumor immune response.
By application, the cancer immunotherapy market is segmented as lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and other applications. The lung cancer market held the largest share in 2015 and is expected to lead the market during the analysis period owing to high incidence of lung cancer. Hospitals in end users held the largest market share of cancer immunotherapy market in 2015, and is projected to show the highest growth rate during the analysis period due to the extensive use of cancer immunotherapy in the hospitals.
Geographically, the global cancer immunotherapy market is analyzed by four regions, namely, North America, Europe, Asia-Pacific, and LAMEA. North America was the highest revenue contributor in 2015. This is attributed to the ample amount of expenditure in healthcare, well-established healthcare system, and high incidence of cancer. However, Asia-Pacific region is projected to be grow with the highest CAGR during the analysis period, owing to rise in healthcare expenditure, increase in per capita income, and improvement in healthcare infrastructure.
The Major Key Players Are:
Amgen Inc., Advaxis Inc., Merck & Co., Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Bayer AG, Immunomedics Inc., and Astrazeneca plc.
Inquire before buying @ https://www.alliedmarketresearch.com/purchase-enquiry/2244
Key Findings of the Cancer Immunotherapy Market:
• By technology type, the monoclonal antibody segment accounted for the largest market share for technology segment in 2020 and is also estimated to grow at the highest CAGR of 14.5%.
• By application, the lung cancer segment held the highest market share and is anticipated to lead the cancer immunotherapy market growth during the analysis period.
• By region, the U.S. was the major shareholder in the North America cancer immunotherapy market, accounting for 85.12% share in 2020.
• By region, Japan is expected to show the highest growth rate during the analysis period.
Trending Reports in Healthcare Industry
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Source: EIN Presswire